VQ-101 is under clinical development by Vanqua Bio and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VQ-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VQ-101 overview
Small molecules are under development for the treatment of GBA Parkinson's disease, Gaucher disease, idiopathic Parkinson's disease and GBA Lewy body dementia. The drug candidates act by targeting glucocerebrosidase (GCase).
Vanqua Bio overview
Vanqua Bio is a biotechnology company focused on developing novel therapies for Parkinson’s disease and associated neurological disorders. It is investigating small molecule modulators of lysosomal targets that have genetic linkages to glucocerebrosidase mutations in Parkinson’s disease (GBA PD). The company harnesses its unique technology platform and biology capabilities to advance novel central nervous system (CNS) therapeutics. Its candidate is based on Silverstein Foundation-funded research at Northwestern University. Vanqua Bio is headquartered in Chicago, Illinois, the US.
For a complete picture of VQ-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
